subtype and centroblastic (including monomorphic, centrocytoid and multilobated subtypes) NHL, is of clinical significance with regard to parameters at presentation, including specific localizations, response to therapy, patterns of relapse as well as clinical outcome (overall and disease-free survival), in order to investigate whether it may be justifiable to draw therapeutic consequences from the histological subclassification of large B-cell NHL.
PATIENTS AND METHODS

Patients
For this retrospective study, all patients diagnosed as having an immunoblastic B-cell NHL were retrieved from the files of the Lymphoma Review Panel of the Comprehensive Cancer Center Amsterdam (CCCA) (n = 45). Patients treated according to the guidelines of the CCCA between 1984 and 1994 were analysed for this study. Patients diagnosed as having a centroblastic NHL (monomorphic, centrocytoid and multilobated subtypes, further called centroblastic NHL) and centroblastic polymorphic subtype NHL by the CCCA Lymphoma Review Panel and who were treated in the same period according to the CCCA guidelines in the Netherlands Cancer Institute were used as reference groups (n = 198) . The patients included into this study were all previously untreated. The patients with a centroblastic or centroblastic polymorphic NHL were all treated in the Netherlands Cancer Institute. From the 45 patients with an immunoblastic NHL, 30 patients were treated in the Netherlands Cancer Institute and 15 patients in 5 other hospitals connected to the Comprehensive Cancer Center Amsterdam. As stated above, the treatment guidelines were similar for all institutes.
Clinical records were reviewed (JWB, EMW) and the following parameters at presentation were recorded: age, stage, performance status, sex, LDH, number and localization of extranodal sites, bulky disease (defined as a mass ≥ 5 cm) and the presence of Bsymptoms. The therapeutic regimen was recorded, including information on the composition of the chemotherapeutic schedules, dose reduction of the chemotherapy and radiotherapy data. Response to therapy, time to relapse, second-line therapy for relapses, time and cause of death, date last seen and disease status at the time of review (alive with or without disease) were included.
Patients were excluded from this study on the following criteria: a recognized disease phase of a follicular centrocytic/centroblastic NHL or another type of low-grade B-cell NHL, with subsequent transformation to a large B-cell NHL, human immunodeficiency virus (HIV) related NHL, secondary NHL after previous treatment of an unrelated malignancy and proven T-cell phenotype upon review. Patients of whom no histological slides were available for review and patients with inadequate histological or incomplete clinical data (two or more prognostic parameters lacking) were also excluded from this study.
Histology
All cases were originally diagnosed and classified according to the Kiel-classification and Working Formulation by the CCCA Lymphoma Review Panel, consisting of at least three experienced haematopathologists. In all cases, a minimum panel of immunohistochemical markers was available, including CD20 (L26), MB2, CD45RO (UCHL 1), CD43 (MT1) and CD45RA (LCA) and in later years also including CD3, CD30 and CD79a (JCB 117) .
From 229 cases (45 patients with immunoblastic NHL and 184 patients with centroblastic or centroblastic polymorphic subtype NHL), histological slides were still available for review, and these cases were reclassified according to the updated Kiel classification by two haematopathologists, independently from each other (DdJ, PvH). In case of discrepancy between the reviewers or with the original CCCA panel diagnosis, cases were reviewed together to come to a consensus diagnosis. Immunohistochemical studies were completed, if necessary. According to the criteria defined by the updated Kiel classification (Lennert and Feller, 1990) (and adopted by the recent WHO classification proposal), immunoblastic B-NHL was defined by a tumour cell population of ≥ 90% immunoblasts, centroblastic NHL as ≤ 10% immunoblasts and centroblastic polymorphic subtype NHL as between 10-90% immunoblasts. A further subdivision was recorded as group 1 = 10-25% immunoblasts, group 2 = 25-50% immunoblasts, group 3 = 50-75% immunoblasts and group 4 = 75-90% immunoblasts of the total malignant B-cell infiltrate. In order to investigate the additional value of the immunohistochemical identification of immunoblasts in quantifying their number, an immunohisto chemical analysis was performed with the plasma cell-related antibodies CD138 (Syndecan-1, 1D4/B-B4 antibody, Serotec Ltd, Oxford, UK) (Wijdenes et al, 1996) and VS38c (Dako A/S, Glostrup, Denmark) on 19 cases of immunoblastic NHL, 21 cases of centroblastic NHL and 21 cases of polymorphic centroblastic NHL. Subclassification on the basis of this additional immunohistochemical information was performed without knowledge of the previous diagnosis.
Statistical analysis
Overall survival and disease-free survival curves were estimated using the Kaplan-Meier method. The univariate associations between different clinical and histological features with overall and disease-free survival were tested with the log-rank test. Stratified log-rank tests were performed to study the prognostic value of histological subclassification, adjusting for the international prognostic index (Shipp et al, 1993) . In addition to the stratified log-rank tests, the Cox proportional hazards model was used. A step forward procedure was performed to study the risk associated with different histological subtypes, adjusting for the international prognostic index (Shipp et al, 1993) , sex, B-symptoms, bulky disease (≥ 5 cm) and bone marrow involvement. Association of different clinical features with histological cell type was studied using the Pearson chi-square test. All reported P-values were obtained from two-sided tests. P-values of > 0.05 are reported as not significant.
RESULTS
Histology
Forty-five cases with immunoblastic NHL and 198 cases with centroblastic or centroblastic polymorphic subtype were retrieved from the files of the Lymphoma Review Panel of the CCCA between 1984 and 1994.
After exclusion according to the above-mentioned criteria, 177 patients with large B-cell NHL were included in this study. Thirty-six (20.3%) of the patients were diagnosed to have an immunoblastic B-cell NHL (IB NHL). Of the 45 originally retrieved cases of immunoblastic NHL, 2 cases were excluded bacause of lack of enough clinical data, 3 cases were excluded on the basis of not-proven B-cell phenotype (most probably T-NHL), 3 cases were reclassified as centroblastic polymorphic subtype NHL upon review (group 4, between 75 and 90% immunoblasts) and 1 patient was recognized as having a follicular centrocytic/ centroblastic NHL transformed to an immunoblastic B-cell NHL at the time of the first presentation.
Of the 198 originally retrieved cases of centroblastic NHL or centroblastic polymorphic subtype NHL, 57 cases were excluded for the following reasons: no histological slides available for review (14 cases), inadequate histology (3 cases), incomplete clinical data (27 cases), HIV-related NHL (9 cases), follicular centroblastic/centrocytic NHL transformed to a centroblastic NHL and centroblastic polymorphic subtype respectively at the time of presentation (2 cases) and development of a large B-cell NHL after previous treatment for Hodgkin's disease (2 cases). Of the 141 included cases, 69 (39%) of the cases were classified as centroblastic polymorphic subtype NHL (CB-Poly NHL) and 72 (40.3%) as centroblastic NHL (CB NHL). In 8/141 (5.7%) cases, review resulted in divergence of classification between the centroblastic and centroblastic polymorphic subtype (2 patients originally diagnosed to have a CB NHL had a CB-Poly NHL upon review, 6 patients originally diagnosed to have a CB-Poly NHL had a CB NHL upon review). No cases with a centroblastic or centroblastic polymorphic subtype NHL were reclassified as immunoblastic NHL. Thus, in the total group of 177 patients, divergence in histological subclassification between the two haematopathologists occurred in 11 patients (6.2%). The intraobserver variability for the two haematopathologists (all slides were reviewed twice with an interval of at least 2 months) were 6% (n = 10) and 10% (n = 18) respectively. In case of discrepancy between the first and second observation and in case of discrepancy between the two observers, a consensus diagnosis was made between the two haematopathologists.
Immunohistochemical staining with CD138 (Syndecan-1, 1D4/B-B4) and VS38c in 61 cases of large B-cell NHL showed strong staining of reactive plasma cells in all cases. Both markers were quite sensitive to decline of staining intensity upon long-term storage of archival unstained paraffin sections. With optimal tissue quality, reliable and reproducible staining of immunoblasts could be achieved with a lower intensity than the concomitant reactive plasma cells (Figure 1) . Overall, immunohistochemical identification of immunoblasts with CD138 and VS38c was insufficiently reliable to add significantly to the quantification of immunoblasts and is probably not useful for the subclassification of large B-cell NHL.
Clinical parameters at presentation
The clinical characteristics at presentation are summarized in Table 1 .
Patients with an immunoblastic NHL tended to be older than patients with polymorphic centroblastic or centroblastic NHL. The patients with an immunoblastic NHL presented more frequently with stage I or II and one extranodal site than patients with a polymorphic centroblastic or centroblastic NHL. No major differences were found between the subentities of the diffuse large B-cell NHL with regard to the other prognostic criteria according to the International Prognostic Index (IPI) according to Shipp et al (1993: performance status, serum concentrations of LDH, number of extranodal sites [≤ 1 versus > 1], stage). In addition, the distribution of prognostic groups according to the IPI (Shipp et al, 1993) was similar for the three histologic subentities (Table 1) .
The patients with polymorphic centroblastic NHL tended to present more often with bone marrow involvement than patients with immunoblastic or centroblastic NHL (Table 1) .
The extranodal NHL localizations at presentation are summarized in Table 2 . It should be noted that none of the subtypes of large B-cell NHL showed preference for localization in a particular site, except localization of centroblastic NHL in the thyroid. The numbers are, however, too small to draw definite conclusions.
There were no differences in localization and frequency of extranodal relapses.
Therapy
The majority of the patients (52%, 92/177) were treated with CHOP-(like) regimens and radiotherapy. Thirty-four patients (19.2%) received only CHOP-like regimens, 47 patients (26.6%) were treated only with radiotherapy (the majority of the patients treated only with radiotherapy had stage I or II and were treated before 1990). According to the CCCA guidelines, 11 of these 47 patients should have received chemotherapy because of stage and/or bulky disease. (Anthracycline containing) chemotherapy was omitted for the following reasons: erroneous initial diagnosis of seminoma in a patient with centroblastic polymorphic subtype NHL, patient's refusal (1 patient with centroblastic NHL, 1 patient Four patients did not receive any therapy at all because of rapid deterioration (2 patients with immunoblastic NHL), very old age (1 patient with centroblastic polymorphic NHL, 91-year-old patient) and no evidence of disease after surgical resection (1 patient with centroblastic NHL). The dose reductions and response to the CHOP-like regimens and radiotherapy are summarized in Table 3 . The response to treatment was similar in the different histological subgroups.
Dose reductions occurred more frequently in patients with a centroblastic polymorphic or centroblastic NHL than in patients with an immunoblastic NHL.
Clinical outcome
The median follow-up for all 177 patients was 5 years and 4 months and was similar in all histological subtypes (5 years and 4 months for the 72 patients with centroblastic NHL, 5 years and 3 months for the 69 patients with centroblastic polymorphic subtype NHL and 5 years and 8 months for the 36 patients with immunoblastic NHL).
The clinical outcome (last evaluation in December 1996) is summarized in Table 4 . The major cause of death was NHL in all three groups.
Multivariate analysis (including sex, B-symptoms, bulky disease ≥ 5 cm, bone marrow involvement, the international prognostic index) showed only prognostic significance in relation to overall and disease-free survival for the international prognostic index (IPI).
In addition to the IPI, histological subclassification had an independent prognostic significance. With regard to disease-free survival, the IPI risk group 2, 3 and 4 together showed a risk ratio of 2.12 compared with risk group 1 (P = 0.0001). Patients with an immunoblastic NHL or centroblastic polymorphic NHL showed in comparison to the patients with a centroblastic NHL a risk ratio of Shipp et al (1993) . 2.01 (P = 0.0105) and 2.02 (P = 0.0019) respectively. With regard to overall survival, the IPI risk group 2, 3 and 4 together showed a risk ratio of 2.735 (P = 0.0001) in comparison with risk group 1; the immunoblastic or centroblastic polymorphic NHL subtypes showed a risk ratio of 1.819 (P = 0.0391) and 1.712 (P = 0.0248) respectively in comparison with centroblastic NHL.
The overall survival and disease-free survival curves by histologic subtypes are shown in Figure 2 . The 5-year disease-free survival for patients with a centroblastic NHL was 53.4%, for patients with an immunoblastic or centroblastic polymorphic subtype NHL 26.9% and 32% (log-rank test stratified by the risk groups as defined by the IPI: P = 0.004); the 5-year overall survival was 56.3%, 39.1% and 41.6% respectively (log-rank test, stratified by the risk groups as defined by the IPI: P = 0.022). The patients with centroblastic NHL thus had a better disease-free and overall survival compared with patients with a centroblastic polymorphic subtype or immunoblastic NHL, even when adjusting for the IPI.
This retrospective study confirms the value of the IPI criteria (Shipp et al, 1993) : the 5-year overall survival of patients with 0 or 1 risk factor (risk group 1) was 61.8% vs 26.6% for the patients with 2 or more risk factors (risk groups 2-4; log-rank test, stratified by histological subtype: P < 0.0001); the 5-year disease-free survival for the patients with 0 or 1 risk factor (risk group 1) was 51.4% vs 21.4% for the patients with 2 or more risk factors (risk groups 2-4; log-rank test, stratified by histological subtype: P < 0.0001).
We investigated the significance of the relative percentage of immunoblasts present in the centroblastic polymorphic subtype. Owing to the small numbers in the groups, the significance of the of the percentage of immunoblasts on overall or disease free survival in these subgroups could not be reliably interpreted.
DISCUSSION
This retrospective study shows that patients with an immunoblastic and centroblastic polymorphic subtype NHL have a worse prognosis than patients with a diffuse centroblastic NHL, independent of the clinical prognostic criteria as defined by the IPI (Shipp et al, 1993) . Although the initial response to therapy was the same for the three histological subtypes, the patients with immunoblastic and centroblastic polymorphic subtype NHL had a higher risk of recurrence of their NHL than the patients with centroblastic NHL, resulting in a significantly worse disease-free and overall survival. The patients with a centroblastic NHL did show a better outcome, despite the fact that dose reductions in their chemotherapy schedule occurred more frequently than in the patients with an immunoblastic NHL and with a similar frequency in the patients with a centroblastic polymorphic NHL (Table 3) . Therefore, the dose intensity of treatment cannot explain the different outcome in the three histological subgroups.
Our findings are consistent with the results of the recent study of Engelhard et al (1997) and former publications (Rosenberg et al, 1982; Stein and Dallenbach, 1992) . Other authors, however, could not demonstrate a prognostic significance of histological subtyping in large B-cell NHL (Simon et al, 1988; Kwak et al, 1991; Dumont et al, 1992; Koza et al, 1992) . The reason for this discrepancy is not clear, but may be due to the relatively small number of patients with immunoblastic NHL and/or a different setting of criteria in most of these retrospective studies. The discrepancy of the outcome of these studies can also be explained by the hypothesis that the immunoblastic, centroblastic polymorphic subtype and centroblastic NHL are not separate disease entities, but may represent the extremes of one biological entity.
As many other studies have done, our study confirms the value of the IPI (Shipp et al, 1993) for patients with NHL of intermediate and high-grade malignancy.
In addition to the prognostic significance of histological subtyping of large B-cell NHL, we analysed whether the different histological categories are related to specific differences in clinical presentation. The patients with immunoblastic NHL tended to be older than the patients with centroblastic or centroblastic polymorphic subtype NHL. This has also been reported by Kwak et al (1991) . The patients with an immunoblastic NHL presented more frequently with stage I or II and with one extranodal site than patients with a centroblastic or centroblastic polymorphic subtype of NHL.
None of the subtypes of large B-cell NHL showed preference for localization in a particular site, except localization of centroblastic NHL in the thyroid, but the numbers are too small to draw definite conclusions. We found also no major differences in the sites of recurrent disease for the histological subtypes of large Bcell NHL.
Several studies report a more frequent involvement of central nervous system and bone marrow in patients with an immunoblastic NHL (Koza et al, 1992; Rodriquez and Khan, 1995) . This finding has been used to justify central nervous system prophylaxis in the treatment schedules of these patients (Koza et al, 1992) . Our findings, however, give no support for this approach. These results are in line with other studies (Simon et al, 1988; Murphy et al, 1989; Hvizdala et al, 1991; Kwak et al, 1991; Dumont et al, 1992; Engelhard et al, 1997; Bos et al, 1998) . Therefore, histological subclassification of large B-cell NHL should not be used to select patients for central nervous system prophylaxis.
The reproducibility of the subclassification of the large B cell NHL is a well-known problem. Although the rate of discrepancy between the two contributory haematopathologists was within acceptable limits in this study (6.2% of all cases), additional immunohistochemical stainings that can contribute to improvement of the reproducibility and discrimination between the several subgroups of NHL might be helpful. In our study, immunohistochemical staining with CD138 (Syndecan-1) and VS38c, both staining plasma cells and plasmacytoid blasts, was insufficiently reliable to add significantly to the quantification of immunoblasts. This can be partly explained by the fact that this marker was quite sensitive to decline of staining intensity upon storage of archival unstained paraffin sections. In acquired immunodeficiency syndrome related large B-cell NHL CD138 (Syndecan-1) expression was only found in the immunoblastic subtype, although the degree of expression varied considerably from 0 to 75% (Carbone et al, 1998) , supporting the view that immunohistochemical staining with CD138 and similar antibodies alone is of minor additional value for subclassification of large B-cell NHL.
The results of the study of Engelhard et al (Engelhard et al, 1997) and our study support the prognostic significance of morphological distinction between immunoblastic, centroblastic polymorphic and centroblastic NHL. This finding merits further exploration in larger prospective studies with uniformly staged patients treated with standardized therapies to judge the value of histological subclassification of large B-cell NHL as a guideline in therapy choice. Immunohistochemical and molecular biological data may prove to be of additional value to distinguish reproducible subentities of diffuse large B-cell NHL and may support the inherently subjective analysis of cellular morphology. 
